Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils.
Gerbils show a neurokinin (NK)1 receptor pharmacological profile, which is similar to that observed in humans, and thus have become a commonly used species to test efficacy of NK1 receptor antagonists. The aim of this study was to determine whether systemic administration of the NK1 receptor antagonist GR-205171 produced anxiolytic-like effects in the elevated plus maze and in a novel contextual conditioned fear test using fear-potentiated startle (FPS). On the elevated plus maze, treatment with GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing produced anxiolytic-like effects in an increasing dose-response manner as measured by the percentage of open arm time and percentage of open arm entries. For contextual fear conditioning, gerbils were given 10 unsignaled footshocks (0.6 mA) at a 2-min variable interstimulus interval in a distinctive training context. Twenty-four hours after training, gerbils received treatment of GR-205171 at 0, 0.3, 1.0, and 5.0 mg/kg doses, 30 min before testing in which startle was elicited in the same context in which they were trained. Contextual FPS was defined as an increase in startle over pretraining baseline values. All drug dose levels (0.3, 1.0, and 5.0 mg/kg) significantly attenuated contextual FPS when compared with the vehicle control group. A control group, which received testing in a different context, showed little FPS. These findings support other evidence for anxiolytic activity of NK1 receptor antagonists and provide a novel conditioned fear test that may be an appropriate procedure to test other NK1 antagonists for preclinical anxiolytic activity in gerbils.
Heldt
Scott A
SA
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. sheldt@emory.edu
Davis
Michael
M
Ratti
Emiliangelo
E
Corsi
Mauro
M
Trist
David
D
Ressler
Kerry J
KJ
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005239:Fear / Q000187:drug effects*; D005849:Gerbillinae; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D023421:Models, Animal; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D013216:Reflex, Startle / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; D013777:Tetrazoles; C103207:vofopitant
Neuroscience. 1995 Dec;69(4):1205-21
8848108
Pharmacol Biochem Behav. 1994 Sep;49(1):171-6
7816869
Psychophysiology. 2001 May;38(3):383-90
11352126
Peptides. 1990 Jan-Feb;11(1):163-7
1692991
Exp Brain Res. 1988;73(2):354-6
2463935
Psychopharmacology (Berl). 1987;92(2):180-5
3110839
Physiol Behav. 1996 Oct;60(4):1183-6
8884951
Pharmacol Biochem Behav. 1991 Aug;39(4):903-9
1763110
Behav Neurosci. 1995 Jun;109(3):379-87
7662148
Mol Imaging Biol. 2005 Jul-Aug;7(4):262-72
16155744
Brain Res. 2006 Mar 17;1078(1):151-8
16494851
Amino Acids. 2006 Oct;31(3):251-72
16820980
Behav Pharmacol. 2000 Sep;11(6):495-504
11103915
Biol Psychiatry. 2009 Jul 1;66(1):94-7
19200949
Neuropsychopharmacology. 2002 Sep;27(3):371-9
12225694
Eur J Pharmacol. 2001 Nov 30;432(1):43-51
11734186
Pharmacol Biochem Behav. 1994 Sep;49(1):133-41
7816864
Behav Neurosci. 1992 Apr;106(2):274-85
1590953
Pharmacol Rev. 1994 Dec;46(4):551-99
7534932
Brain Res Mol Brain Res. 1993 Apr;18(1-2):43-58
7683074
Eur J Pharmacol. 1994 Dec 27;271(2-3):481-7
7705448
Sci Am. 1994 Jun;270(6):50-7
8023118
Biol Psychiatry. 2007 Apr 15;61(8):1002-6
16950220
J Neurosci. 1995 Mar;15(3 Pt 2):2301-11
7891168
Eur J Pharmacol. 2001 Feb 2;412(3):255-64
11166289
Acta Physiol Scand. 1992 Nov;146(3):341-8
1282765
Am J Psychiatry. 2006 Apr;163(4):637-43
16585438
Biol Psychiatry. 2005 Jul 15;58(2):132-42
16038684
Pharmacol Biochem Behav. 1986 Mar;24(3):525-9
2871560
Behav Neurosci. 1992 Feb;106(1):72-80
1554439
Biophys J. 1992 Apr;62(1):59-60
1376175
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4280-5
15024126
Biol Psychiatry. 2006 Oct 1;60(7):760-6
16631127
Behav Neurosci. 2000 Aug;114(4):749-59
10959534
Pharmacol Rev. 2002 Jun;54(2):285-322
12037144
Eur J Pharmacol. 1996 Sep 5;311(1):7-14
8884230
Science. 1992 May 1;256(5057):675-7
1585183
Curr Pharm Des. 2005;11(12):1529-47
15892660
J Neurosci Methods. 1985 Aug;14(3):149-67
2864480
Psychopharmacology (Berl). 2001 Oct;157(4):358-67
11605094
Neuropharmacology. 1991 Dec;30(12A):1263-7
1787880
Psychopharmacology (Berl). 1995 Apr;118(3):316-23
7617825
Behav Pharmacol. 2001 Nov;12(6-7):497-508
11742144
Neuropeptides. 1998 Feb;32(1):1-49
9571643
Br J Pharmacol. 2006 Feb;147(3):316-23
16331282
Science. 2008 Mar 14;319(5869):1536-9
18276852
Brain Res. 2001 Oct 12;915(2):170-5
11595206
Brain Res. 1999 Nov 27;848(1-2):90-5
10612700
Life Sci. 1998;63(25):2227-32
9870708
Br J Pharmacol. 2006 May;148(1):39-45
16501582
Eur J Neurosci. 2003 May;17(9):1736-46
12752772
Neuroreport. 1997 Mar 3;8(4):1031-4
9141086
Behav Brain Res. 2004 Oct 5;154(2):501-10
15313039
Curr Drug Targets. 2006 Aug;7(8):975-92
16918326
Behav Brain Res. 2002 Jul 18;133(2):363-8
12110470
J Pharmacol Exp Ther. 2002 May;301(2):536-42
11961054
Eur J Pharmacol. 1994 Sep 1;262(1-2):171-5
7529183
Brain Res. 1986 Sep 3;381(2):393-6
2428438
Psychopharmacology (Berl). 1979 Mar 29;62(1):1-7
35808
Neuropsychopharmacology. 2004 Feb;29(2):385-92
14666114
Neuropsychopharmacology. 2002 Sep;27(3):357-70
12225693
Pharmacol Biochem Behav. 1996 May;54(1):21-30
8728535
Behav Brain Res. 1994 Jul 29;63(1):81-8
7524534
Life Sci. 2004 Feb 6;74(12):1445-63
14729395
Eur J Pharmacol. 1999 Jun 30;375(1-3):51-60
10443564
Psychopharmacology (Berl). 1989;99(1):48-53
2528779
J Neurosci. 1997 Dec 1;17(23):9353-60
9364080
Psychopharmacology (Berl). 1992;106(1):102-10
1738787
Neuropsychobiology. 1988;20(2):82-6
3151011
Neuropsychopharmacology. 2003 Apr;28(4):654-63
12655310
Behav Brain Res. 2000 Jun 1;110(1-2):83-95
10802306
J Comp Neurol. 2005 Oct 3;490(4):335-53
16127708
Science. 1998 Sep 11;281(5383):1640-5
9733503
J Comp Neurol. 2002 May 20;447(1):82-97
11967897
Biol Psychiatry. 2007 Feb 1;61(3):389-95
16730332
Behav Brain Res. 1986 Aug;21(2):119-27
2428383
Neuropharmacology. 2003 Aug;45(2):231-41
12842129
Eur J Pharmacol. 1991 May 17;197(2-3):237-8
1717291
Neuropharmacology. 2003 Mar;44(4):516-23
12646288
Br J Pharmacol. 1991 Oct;104(2):292-3
1665729
Neuropeptides. 1994 Apr;26(4):253-60
7518054
J Comp Neurol. 1998 Sep 7;398(4):473-90
9717704
Neurosci Biobehav Rev. 1997 Nov;21(6):801-10
9415905
Neuroendocrinology. 1987 Jun;46(1):75-81
2441310
Pharmacol Biochem Behav. 1995 Oct;52(2):297-303
8577794
Eur J Pharmacol. 2005 Jan 10;507(1-3):99-105
15659299
Psychophysiology. 1997 Jul;34(4):451-8
9260498
Braz J Med Biol Res. 1997 Mar;30(3):289-304
9246227
Ann N Y Acad Sci. 1985;448:255-74
2411182
Int J Psychophysiol. 1999 Apr;32(1):63-73
10192009
J Abnorm Psychol. 1996 Feb;105(1):89-96
8666715
Behav Brain Res. 2007 Sep 4;182(2):301-7
17208313
Regul Pept. 1996 Aug 27;65(1):45-53
8876035
Behav Pharmacol. 1994 Jun;5(3):369-373
11224289
Pharmacol Biochem Behav. 1997 Nov;58(3):747-52
9329068